Canton Strategic (CNTN) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Canton Strategic (CNTN) over the past year, losing 49.2% versus a loss of 50.6%. Minerva Neurosciences is the larger company by market cap ($99.7 million vs $98.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | NERV |
|---|---|---|
| Share price | $1.21 | $2.00 |
| Market cap | $98.78M | $99.67M |
| 1-day change | -1.63% | -5.66% |
| YTD return | -60.07% | -50.25% |
| 1-year return | -50.61% | -49.24% |
| 5-year return | — | -76.42% |
| P/E ratio (TTM) | 20.17 | — |
| EPS (TTM) | $0.06 | $-33.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-35.92M | $-293.42M |
| 52-week high | $5.83 | $8.80 |
| 52-week low | $1.19 | $1.96 |
| Distance from 52-week high | -79.25% | -77.27% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +416.50% |
| Average volume | 763.63K | 164.71K |
| Shares outstanding | 81.64M | 49.84M |
| Employees | 12 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
CNTN vs NERV FAQ
Which is bigger, Canton Strategic or Minerva Neurosciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $99.67M compared with $98.78M for Canton Strategic (CNTN).
Which stock has performed better over the past year, CNTN or NERV?
NERV returned -49.24% over the past 12 months, compared with -50.61% for CNTN (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.